On Wednesday, August 14, Titan Pharmaceuticals TTNP will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
Wall Street analysts see Titan Pharmaceuticals reporting a loss of 25 cents per share on revenue of $930,000.
In the same quarter last year, Titan Pharmaceuticals posted a loss of 4 cents on sales of $2.67 million. If the company were to match the consensus estimate, earnings would be up 525.00%. Revenue would be down 65.14% on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 |
| EPS Estimate | -0.260 | -0.31 | -0.05 | -0.13 |
| EPS Actual | -0.340 | -0.62 | -0.11 | -0.04 |
Stock Performance
Over the last 52-week period, shares are down 21.61%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.
Over the past 90 days, analysts have generally adjusted their estimates lower for EPS and revenues. The most common rating by analysts on Titan Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
